Sign up
Pharma Capital

ValiRx PLC gets go-ahead to expand and accelerate early-stage cancer study

George Morris, chief operations officer at ValiRx Plc (LON:VAL) tells Proactive the've been given the go-ahead by regulators to expand and accelerate their early-stage cancer study.

The Medicines and Healthcare Regulator Agency and Research Ethics Committee are allowing them to substantially raise the dosing of VAL201, a treatment for metastatic prostate cancer and other solid tumours.

They'll be doing this to find the correct therapeutic levels of treatment to administer in order to try to stop the disease’s spread.

 

View full VAL profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.